There is a complete cure for limited scleroderma
There is currently no known complete cure for limited scleroderma; while advanced therapies such as cellular treatments and stem cell transplantation can induce drug-free remissions or functional improvements in some patients, the disease is generally managed rather than completely cured.
The claim states there is a 'complete cure' for limited scleroderma (a form of systemic sclerosis or localized scleroderma). Medical literature confirms that scleroderma is a chronic autoimmune and fibrosing condition with no known complete cure. While aggressive modern therapies (such as CAR-T cells, autologous hematopoietic stem cell transplantation, or JAK inhibitors) can achieve deep, drug-free remissions or functional improvements in some patients, these interventions do not constitute a guaranteed complete cure, and the disease often requires ongoing management or carries risks of relapse and chronic tissue damage.
de Carvalho JF, Rodrigues CEM. Is a Functional Cure Possible in Autoimmune Diseases? Evidence from Trigger Eradication, Transplantation, and Cellular Therapies.. 2026. https://doi.org/10.1007/s40744-025-00816-z
Paper [3] notes that while autoimmune diseases can sometimes achieve sustained remission or a 'functional cure' via intensive therapies like HSCT or CAR-T, they are traditionally considered incurable and such therapies only offer drug-free remission in selected cases rather than a universal complete cure.
See more details
Giacometti E, Martineau J, Petrou IG, Kalbermatten DF, Scampa M. Calcinosis Cutis Universalis: A Review of Therapeutic Strategies and Surgical Management.. 2026. https://doi.org/10.3390/jcm15030959
Paper [5] highlights that management of severe scleroderma-related manifestations like calcinosis cutis remains challenging due to the absence of standardized treatment guidelines and heterogeneous, often partial efficacy of current therapies.
Zheng R, Zou L, Li SC, Lu M. JAK inhibitors for the treatment of juvenile localized scleroderma: a case report and literature review.. 2026. https://doi.org/10.1186/s12969-026-01186-8
Paper [11] discusses juvenile localized scleroderma as a chronic and challenging disease where current treatments only offer partial improvements or act as alternatives for resistant cases, rather than providing a complete cure.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt